譚木匠(00837.HK)3月31日董事會審議並批准年度業績
格隆匯3月17日丨譚木匠(00837.HK)公佈,謹定於2022年3月31日星期四於香港九龍旺角通菜街1A-1L號威達商業大廈7樓708室會議室舉行董事會會議,目的如下:
1.審議並批准集團截至2021年12月31日止年度的經審計年度業績;
2.審議並批准依照香港聯合交易所有限公司證券上市規則須予刊登的集團截至2021年12月31日年度業績公吿草稿;
3.審議並批准派付截至2021年12月31日止年度的末期股息(如有);
4.審議並批准暫停辦理股份過户登記手續(如有需要);及
5.處理任何其他事項(如有)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.